Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPI 287 in Primary Four Repeat Tauopathies
NCT02133846Phase 1Completed
- Sponsor
- University of California, San Francisco
- Start
- May 2014
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of abeotaxane in Corticobasal Syndrome (CBS) and progressive supranuclear palsy (PSP) (4 arms), sponsored by University of California, San Francisco. Primary endpoint: Maximum Tolerated Dose at 21 months. Started May 2014; status: completed.
02
Drugs
abeotaxane
03
Conditions
Corticobasal Syndrome (CBS)progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NCT02133846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02133846.